Difference between revisions of "Tyrosine kinase inhibitors"
Jump to navigation
Jump to search
(create) |
(→Use) |
||
| (6 intermediate revisions by the same user not shown) | |||
| Line 5: | Line 5: | ||
* Gefitinib (Iressa). | * Gefitinib (Iressa). | ||
* Erlotinib (Tarceva). | * Erlotinib (Tarceva). | ||
Others - used in [[RCC]]:<ref>URL: [http://dtb.bmj.com/content/49/11/129.abstract http://dtb.bmj.com/content/49/11/129.abstract]. Accessed on: 3 October 2014</ref> | |||
* [[Sunitinib]] (Sutent). | |||
* Sorafenib (Nexavar). | |||
* Pazopanib (Votrient). | |||
==Use== | |||
*[[Lung adenocarcinoma]]. | |||
*[[Adenosquamous carcinoma of the lung]].<ref name=pmid23769878>{{Cite journal | last1 = Song | first1 = Z. | last2 = Lin | first2 = B. | last3 = Shao | first3 = L. | last4 = Zhang | first4 = Y. | title = Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma. | journal = J Chin Med Assoc | volume = 76 | issue = 9 | pages = 481-5 | month = Sep | year = 2013 | doi = 10.1016/j.jcma.2013.05.007 | PMID = 23769878 }}</ref> | |||
*[[Clear cell renal cell carcinoma]].<ref name=pmid25467013>{{Cite journal | last1 = Elaidi | first1 = R. | last2 = Harbaoui | first2 = A. | last3 = Beuselinck | first3 = B. | last4 = Eymard | first4 = JC. | last5 = Bamias | first5 = A. | last6 = De Guillebon | first6 = E. | last7 = Porta | first7 = C. | last8 = Vano | first8 = Y. | last9 = Linassier | first9 = C. | title = Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma. | journal = Ann Oncol | volume = 26 | issue = 2 | pages = 378-85 | month = Feb | year = 2015 | doi = 10.1093/annonc/mdu552 | PMID = 25467013 }}</ref><ref name=pmid21484781>{{Cite journal | last1 = Verma | first1 = J. | last2 = Jonasch | first2 = E. | last3 = Allen | first3 = P. | last4 = Tannir | first4 = N. | last5 = Mahajan | first5 = A. | title = Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. | journal = Cancer | volume = 117 | issue = 21 | pages = 4958-65 | month = Nov | year = 2011 | doi = 10.1002/cncr.26138 | PMID = 21484781 }}</ref> | |||
==See also== | ==See also== | ||
*[[Epidermal growth factor receptor inhibitors]]. | *[[Epidermal growth factor receptor inhibitors]]. | ||
*[[Cancer drugs]]. | *[[Cancer drugs]]. | ||
==References== | |||
{{Reflist|1}} | |||
[[Category:Clinical]] | [[Category:Clinical]] | ||
[[Category:Drugs]] | |||
Latest revision as of 01:35, 5 June 2015
Tyrosine kinase inhibitors, abbreviated TKIs, are a group of drugs that inhibit the action of tyrosine kinases.
The category includes many cancer drugs - including:
- Imatinib (Gleevec).
- Gefitinib (Iressa).
- Erlotinib (Tarceva).
- Sunitinib (Sutent).
- Sorafenib (Nexavar).
- Pazopanib (Votrient).
Use
See also
References
- ↑ URL: http://dtb.bmj.com/content/49/11/129.abstract. Accessed on: 3 October 2014
- ↑ Song, Z.; Lin, B.; Shao, L.; Zhang, Y. (Sep 2013). "Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.". J Chin Med Assoc 76 (9): 481-5. doi:10.1016/j.jcma.2013.05.007. PMID 23769878.
- ↑ Elaidi, R.; Harbaoui, A.; Beuselinck, B.; Eymard, JC.; Bamias, A.; De Guillebon, E.; Porta, C.; Vano, Y. et al. (Feb 2015). "Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma.". Ann Oncol 26 (2): 378-85. doi:10.1093/annonc/mdu552. PMID 25467013.
- ↑ Verma, J.; Jonasch, E.; Allen, P.; Tannir, N.; Mahajan, A. (Nov 2011). "Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma.". Cancer 117 (21): 4958-65. doi:10.1002/cncr.26138. PMID 21484781.